JP Morgan Maintains Edwards Lifesciences Corp to Overweight with Price Target $120.00

Brokerage firm JP Morgan Maintains its rating on Edwards Lifesciences Corp(NYSE:EW). In a research note issued to the investors, the brokerage major Raises the price-target to $120.00 per share. The shares have been rated Overweight. The rating by JP Morgan was issued on Apr 11, 2016.

In a different note, On Apr 4, 2016, JP Morgan said it Reiterates its rating on Edwards Lifesciences Corp. In the research note, the firm Raises the price-target to $98.00 per share. The shares have been rated ‘Overweight’ by the firm. On Apr 4, 2016, BTIG Research said it Upgrades its rating on Edwards Lifesciences Corp. The shares have been rated ‘Buy’ by the firm. On Apr 4, 2016, Jefferies said it Maintains its rating on Edwards Lifesciences Corp. In the research note, the firm Raises the price-target to $100.00 per share. The shares have been rated ‘Buy’ by the firm. On Apr 4, 2016, Leerink Swann said it Maintains its rating on Edwards Lifesciences Corp. In the research note, the firm Raises the price-target to $93.00 per share. The shares have been rated ‘Outperform’ by the firm. On Apr 4, 2016, BMO Capital said it Maintains its rating on Edwards Lifesciences Corp. In the research note, the firm Raises the price-target to $93.00 per share. The shares have been rated ‘Outperform’ by the firm. Nomura said it Initiates Coverage on Edwards Lifesciences Corp, according to a research note issued on Mar 17, 2016. The shares have been rated ‘Buy’ by the firm.

Edwards Lifesciences Corp (EW) shares turned negative on Fridays trading session with the shares closing down -0.94 points or -0.87% at a volume of 14,61,072. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $107.4. The peak price level was also seen at $107.4 while the days lowest was $105.97. Finally the shares closed at $106.55. The 52-week high of the shares is $109 while the 52-week low is $61.375. According to the latest information available, the market cap of the company is $22,865 M.

Edwards Lifesciences Corp(EW) last announced its earnings results on Feb 2, 2016 for Fiscal Year 2015 and Q4.Company reported revenue of $671.10M. Analysts had an estimated revenue of $648.70M. Earnings per share were $0.63. Analysts had estimated an EPS of $0.62.

Several Insider Transactions has been reported to the SEC. On Apr 6, 2016, Huimin Wang (CVP, Japan & Intercontinental) sold 13,650 shares at $104.12 per share price.Also, On Mar 18, 2016, Michael A Mussallem (Chairman & CEO) sold 59,000 shares at $85.25 per share price.On Feb 22, 2016, Patrick B Verguet (CVP, Europe) sold 5,000 shares at $87.00 per share price, according to the Form-4 filing with the securities and exchange commission.

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. Patients in the hospital setting including high-risk patients in the operating room or intensive care unit are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Company’s products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy Surgical Heart Valve Therapy and Critical Care.

Leave a Reply

Edwards Lifesciences Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Edwards Lifesciences Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.